

**Guerbet Methodology for ABPI Disclosure 2022**

## Guerbet Methodology for ABPI Disclosure 2022

**Prepared by:** Krupa Mehta, Medical Affairs Manager, Guerbet UK

Guerbet strives to conduct itself and our dealings with UK Healthcare Professionals in a manner that is compliant with UK Law, EU Law, MHRA directive and the PMCPA Code of Practice.

For the 2021 disclosure, Guerbet UK is working with the ABPI Code of Practice 2021.

The Disclosure relates to:

- UK HCPs/HCOs and ORDMs where their primary practice is in the United Kingdom. This includes agreements and contracts drawn up between Guerbet affiliates or with Guerbet Headquarters with UK HCPs/HCOs and ORDMs where the service may be conducted within or outside of the UK
- UK HCPs where a fee is paid by the UK affiliate for a service conducted outside of the UK for example as a speaker at a European event.
- ToVs linked to all Guerbet UK products, including prescription only medicines (POMs) and medical devices; over-the-counter (OTC) medicines do not fall within the transparency scope of the ABPI Code. N.B. According to chapter 1 of Part 2 Disclosure Guidelines of the ABPI Code, there is no Guerbet UK obligation to duplicate disclosure data regarding educational grants on the MedTech Europe transparency platform ([www.ethicalmedtech.eu/](http://www.ethicalmedtech.eu/)) if the same data is captured on another disclosure platform (e.g. Disclosure UK).

Exceptions for Disclosure:

- EU HCPs/HCOs and ORDMs contracted to provide services for the UK affiliate either outside or within the UK. In this case the disclosure will be done in the public site of the country where the expert is having their main activity. Guerbet UK will provide disclosure information to the compliance manager in charge of the disclosure in the affiliate.
- EU Contracts that do not directly make Transfers of Value to UK HCPs/HCOs/ORDMs and that are drawn up by Guerbet affiliates or by Guerbet HQ for services in other EU countries are disclosed by the affiliate or by Guerbet HQ according to local regulations.

**Definition:** 'Transfer of Value' as defined by several clauses and supported by supplementary information within the 2021 Code of Practice as follows:

**Clause 1.25** 'Transfer of value' means a direct or indirect transfer of value, whether in cash, in kind or otherwise, made, whether for promotional purposes or otherwise, in connection with the development or sale of medicines. A direct transfer of value is one made directly by a company for the benefit of a recipient. An indirect transfer of value is one made on behalf of a company for the benefit of a recipient or through an intermediate and where the company knows or can identify the recipient that will benefit from the transfer of value

**Clause 10.10** Companies must publicly disclose annually financial details of support of UK health professionals and other relevant decision makers in relation to attendance at events/meetings.

**Clause 28.1** including supplementary information directly relating to **Clause 28.1** Companies must document and publicly disclose annually certain transfers of value made directly or indirectly to health professionals, other relevant decision makers and healthcare organisations located in Europe. This includes any employee of a pharmaceutical company whose primary occupation is that of a practising health professional.

**Individual disclosure:** the transfers of value to individual named Healthcare Professionals (HCPs) Healthcare Organisations (HCO's) and Other Relevant Decision Makers (ORDM)

**Aggregate disclosure:** the transfers of value to HCPs who cannot be named with the exception of transfers of value to HCP's and HCO's in connection with certain Research and development (R&D) activities including clinical trials.

## Scope

Activities where a transfer of value took place which includes but is not limited to Joint Working arrangements, Consultancy fees, Sponsorship of HCO/HCP/ORDM, Support of an HCP/HCO/ORDM to manage an Event, Honoraria, Registration Fees, Travel & Accommodation and Related Agreed Expenses.

Guerbet supports the continued education of HCPs through educational events. These events are organised by a 'Course Director' who is responsible for transactions between themselves and speakers. This is to ensure balanced educational content. Where Transfers of Value are made between Guerbet and the Course Director, these are disclosed in the 2022 Disclosure. Contracts stipulate a declaration of sponsorship on course material and any conflicts of interest must be declared.

## Method

1. All payments were tracked by the Marketing team in preparation for the Annual ABPI Disclosure.
2. The tracker allocates a code for each new agreement and the code acts as the file number. The tracker also records the value and the disclosure preference of the HCP. All Transfers of Value with HCOs are disclosed.
3. The Agreement is generated by an automated form.
4. The tracker file is reconciled with a download from SAP.
5. Membership costs, corporate sponsorships and Transfers of Value to HCOs and ORDs are recorded at Purchase Requisition stage by code.
6. The SAP download is interrogated for all Transfers of Value to this code as well as interrogated for potential 'miscoding' via a key word search.
  - a. Key words include: membership, grant, fee, sponsorship, support, education, meeting, advisory, speaker, chair, event, expense, expert, course.
  - b. Further searches are conducted on organisations with whom Guerbet collaborates

Global Agreements: The UK subsidiary is responsible for approving Global Agreements via Guerbet Headquarters with UK HCPs.

1. The agreement is shared with Guerbet UK.
2. The agreement is checked for local regulatory compliance and disclosure compliance
3. The agreement is recorded in the aforementioned tracker and reconciled back to SAP as mentioned above.

The number of individuals who have agreed to payments being disclosed individually are 5 and as an aggregate 11.

**Consent:** Agreements/contracts made with HCPs, HCOs and ORDMs which outlines Guerbet's intention to disclose transfers of value including the definition outlined in the Code of Practice 2021.

- a. Article 4 of the agreement refers to Regulatory Provisions:  
Item 4.8 states the following:

### **Disclosure of transfer of value**

According to the ABPI code of practice and its implementation of clause "24: Transfers of Value to Health Professionals and Healthcare Organisations" in the UK, Guerbet Laboratories Ltd will proceed to the disclosure of all transfers of value mentioned in the contract in the public site of the country where the expert is having their main activity.

Clause 24.1 of the ABPI code states: Companies must document and publicly disclose certain transfers of value made directly or indirectly to health professionals and healthcare organisations located in Europe.

Please indicate on the consent form if you would prefer individual or aggregate disclosure.

“Individual disclosure” means transfers of value to individual named Healthcare Professionals (HCPs) and Healthcare Organisations (HCO’s)

“Aggregate disclosure” means transfers of value to HCPs who cannot be named with the exception of transfers of value to HCP’s and HCO’s in connection with certain R&D activities including clinical trials.

- b. A disclosure consent form is included in the Appendices of the agreement/contract
- c. In an agreement generated by Guerbet HQ, (Villepinte, Paris) the same Disclosure statement is made in Article 14. The form is attached in the appendices of the agreement

**Agreement/Contract:** A written document between Guerbet Laboratories and the HCP/HCO/ORDM which contains scope, obligations, exclusions, caveats, acknowledgements, rights, details of activity, intellectual property rights and disclaimers.

**Reconciliation:** Consent forms are reconciled with Transfers of Value and compiled into the Disclosure Template.

### Considerations

**Intention:** Guerbet declares intention to disclose within Regulatory Provisions within the Contract: This included the Regulatory provision set out in the Method above and Guerbet’s obligations to disclose transfers of value.

**Consent:** A form indicating ‘Individual’ or ‘Aggregate’ disclosure is returned to Guerbet. A consent form consent form is included within the appendices of the agreement/contract. Returned forms are retained and reconciled according to the 2022 Disclosure. If no agreement for individual disclosure is made the HCP is defaulted to aggregate.

**Exchange rate considerations:** Where the payment details were received in euros the exchange was converted using the prevailing market rate at the time of payment.

**Reporting Period:** Activities contracted by Guerbet UK are short. For Contracts made across two reporting periods, the Disclosure is made in the period that the payment is made. If the agreement outlines more than one Transfer of Value across more than one reporting period, the Transfer of Value will be reported separately for the periods for which the activity has been invoiced.

**Contract Research Organisations (CROs):** Transfers of Value disclosures will be made where CROs engage with HCPs/HCOs/ORDMs on behalf of Guerbet. Consent forms are provided to the CRO.

**Medical Devices Transfers of Value:** Transfers of Value were generally made to support education or for consultancy. Due to the nature of the equipment marketed by Guerbet (be it for use with or independently of Guerbet Pharmaceutical agents) and the roles of those HCPs/HROs/ORDMs contracted, no distinction is made between Medical Devices and Pharmaceutical agents for the 2018 Disclosure and all Transfers of Value are disclosed. Transfers of Value for Medical Devices, usually ‘Voice of the Customer’ projects are not connected with Guerbet Pharmaceutical agents however the HCP/HCO/ORDM that is engaged is often also a user or decision maker for products which could be marketed by Guerbet.

**Over the counter transfers of value:** No over the counter transfers of value are made by Guerbet.

**Joint working with other Pharmaceutical Companies:** Guerbet does not currently collaborate with other pharmaceutical companies and no Transfers of Value have been made based on Joint Working arrangements.

**Individual/Aggregate percentage:** The percentage was calculated by the number of aggregate HCPs and total number of HCPs who consented to disclosure individual Transfers of Value.

**Queries:** Queries raised after pre-disclosure will be investigated and rectified accordingly.

#### **Disclosure Declaration**

All data contained within the 2022 Disclosure is true and correct to the best of our knowledge and I undertake to inform the ABPI Disclosure Team of any changes herein. If any information is found to be inaccurate or deficient, Guerbet UK will undertake to rectify immediately.

Inaccuracies, additions, omissions: Contact [krupa.mehta@guerbet.com](mailto:krupa.mehta@guerbet.com).

**Data Protection:** Enquiries should be sent to [krupa.mehta@guerbet.com](mailto:krupa.mehta@guerbet.com) or [uk.info@guerbet.com](mailto:uk.info@guerbet.com).

**Disclosure withdrawal:** Under General Data Protection Regulation (GDPR) HCPs/HCOs/ORDMs disclosed under Individual Disclosure are entitled to withdraw consent at any time by contacting

Where consent is withdrawn, data will be disclosed in 'Aggregate'.

**Dated and Signed:** 29/03/2023 for and on behalf of Guerbet UK, Avon House, 435 Stratford Road, Shirley, Solihull, B90 4AA Registered in England No. 02940474